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TRANSLATIONAL RELEVANCE
Tumor hypoxia is recognised as a major contributing factor in the progression of prostate cancer.
This study provides the first evidence that a novel unidirectional hypoxia-activated prodrug, OCT1002, effectively targets hypoxic tumor cells; our study shows this occurs both in vitro and in vivo. In a xenograft mouse model of prostate cancer, OCT1002 improves the efficacy of the antiandrogen drug bicalutamide in controlling tumor growth. We have shown that initial treatment of androgen-sensitive tumors with bicalutamide causes vascular collapse and increased hypoxia; however, after 21 days the vasculature recovers. Our evidence shows that OCT1002 causes selective killing of tumor cells with a more malignant genotype. This provides a mechanistic explanation for why patients on hormonal therapy relapse. It also shows that targeting hypoxic tumor cells with OCT1002 offers a means by which malignant progression can be blocked in patients on androgendeprivation therapy.
INTRODUCTION
Hypoxia occurs in most solid tumors and it is known to have a major influence on treatment response to both radiotherapy (1) and chemotherapy (2) . Untreated prostate tumors are no exception and they have been found, in several studies, to have very low median oxygen levels (2.4mmHg; 0.3% oxygen) (3, 4) , which is >12 times lower than oxygen levels found in the normal prostate (30 mmHg; 3.9% oxygen) (5) . Studies have shown that high levels of hypoxia significantly correlate with increasing clinical stage and can predict biochemical failure following radiotherapy (6) . Importantly, hypoxia has also been implicated as a causative factor in malignant progression, with many effects mediated through increased expression of HIF-1 (7) . In addition, hypoxia has been shown to cause genetic instability (8) , gene amplification (9) , endothelial to mesenchymal transition (EMT) (10, 11) and the selection of cells with diminished apoptotic potential and a greater invasive potential (12) (13) (14) (15) .
Hypoxia is therefore a significant impediment to the successful outcome of many cancer treatments.
One approach to blocking the influence of hypoxic tumor cells is to directly target this sub-population with a hypoxia-activated prodrug (HAP); these prodrugs are a diverse group of chemicals that can be reduced in cells when oxygen levels are very low (16, 17) . The majority of HAPs are reduced in single-electron reduction steps, a process which is reversible when oxygen levels increase and is associated with superoxide formation. In contrast, alkylaminoanthraquinone di N-oxides are irreversibly reduced by addition of two electrons on each of the two N-oxide side arms of the anthraquinone ring. This results in formation of metabolically stable reduction products; for this reason it is proposed they should be classified separately as unidirectional HAPs (uHAPs). Currently there are two compounds of therapeutic interest presenting these advantageous properties, namely AQ4N (18) and a recently described deuterated analogue OCT1002 (OncoTherics Ltd) (19) . Under tumorrelevant hypoxic conditions the two sequential 2e − reductions yield the toxic metabolites AQ4 and OCT1001 respectively (5) . These stable reduction products have very high affinity for DNA and they also target topoisomerase II (20) , which can effect a long-term inhibition of both DNA replication and cell cycle traverse (21) . OCT1002 is distinguished from AQ4N by its highly selective deuterium substitution of the 12 hydrogen atoms contained within the two N-oxide side chains (22) . Deuteration can modify the rate of cleavage of covalent bonds to deuterium, creating a deuterium kinetic isotope effect, slowing cytochrome P450 metabolism of the deuterated versions of drug candidates (23).
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Further, non-covalent interactions between molecules can be modified by deuteration (24) , while differences in the polarities of deuterated versus non-deuterated isomers can potentially alter the complex subcellular localization and sequestration properties (25) and contribute to an enhanced intracellular persistence of the activated drug OCT1001 (19) .
To test the effectiveness of these uHAPs in vivo, we routinely utilise a murine LNCaP-luc xenograft model of prostate cancer in our laboratory (11, 26) . This is an ideal system to investigate tumor hypoxia, since LNCaP/LNCaP-luc tumors have a low oxygen level (~6mm Hg; 0.8% oxygen) comparable to that observed in patients. Furthermore, we have used this model to demonstrate that this level falls even further to about 0.1% oxygen upon initiation of bicalutamide treatment, due to vascular collapse (26) . Bicalutamide is a widely used drug used in androgen deprivation therapy (ADT) and provides for effective control of locally advanced prostate cancer prostate tumors. However remissions normally last only about 18-24 months before tumors recur, often as the more highly metastatic castrate resistant prostate cancer (CRPC) (27) . Our previous results led us to hypothesise that the bicalutamide-induced hypoxia may select for cells with a more aggressive phenotype, a selection which we subsequently demonstrated was characterised by up-regulation of several prosurvival genes and a promotion of the EMT phenotype (11) . Notably, when a single dose of uHAP (AQ4N) was administered during the bicalutamide-induced hypoxic phase in this model, tumor growth was significantly delayed (26) . In the current study, we have investigated if a similar growth delay occurs in the same xenograft model when OCT1002 is used alone and in combination with bicalutamide. We also profile genetic changes in response to both bicalutamide and OCT1002 treatment to determine if bicalutamide-induced alterations in genes associated with metastatic progression were blocked by the use of OCT1002.
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MATERIALS AND METHODS
Cell Culture
All cell-lines were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were frozen at low passage number and used within 3-6 passages after thawing. Cells were authenticated by in-house genotyping service and routinely tested as mycoplasma-free (InvivoGen, Table S1 ) on a LC480
Lightcycler (Roche).After normalization to the reference gene(s), relative expression levels of each target gene were calculated using the comparative C T (ΔΔCT) method. qPCR for miR-210 was performed using the miRCURY LNA TM microRNA PCR system (Exiqon, Vedbaek, Denmark) using 20ng template RNA. PCR was performed on the LC480 Lightcycler, normalization was against U6snRNA and relative expression levels calculated using the comparative C T (ΔΔCT) method. All PCR graphs represent the combined results from ≥3 independent biological replicates, unless otherwise indicated.
Western Blotting
Protein was extracted from spheroids using urea buffer. Primary antibodies used were obtained from Cell Signaling Technology unless otherwise stated and comprised: PARP/Cleaved PARP (#9542, 1:1000), Bax (#2772S, 1:500), Bcl-2 (#2876S,1:500), β-actin (#4967,1:1000) and GAPDH (Millipore, ABS16,1:1000). Membranes were blocked in 5% BSA diluted in 1x TBS-T (0.05%) followed by incubation in the appropriate secondary antibody (goat anti-rabbit IgG-HRP (1:10000) or goat antimouse IgG-HRP (1:10000)). Secondary antibodies were purchased from Santa Cruz Biotechnology (Heidelberg, Germany).
In vivo methods
Animal maintenance. In vivo experiments were conducted in accordance with the Animal (Scientific Procedures) Act 1986 and the UKCCCR guidelines for the welfare of animals in experimental neoplasia (28). 8-10 week old male BALB/c immune-compromised (SCID) mice weighing 25-30g (Envigo, Cambridgeshire, UK) were housed under standard laboratory conditions in a temperature controlled (22 º C; 50-55% humidity) pathogen free environment with a 12 hour light-dark cycle. Food and water was supplied ad libitum. All surgical procedures were performed under aseptic conditions and the body temperature of animals was kept constant using heated pads. 
Dorsal skin fold model
Dorsal skin fold (DSF) preparation.
A bespoke transparent DSF 'window chamber' (APJ Trading Co.
Ltd, USA) was attached to the dorsum of mice as previously described (26, 29) . This consisted of a titanium frame with a viewing port into which a tumor fragment was placed. The DSF preparation was then hydrated with sterile saline and closed with a glass coverslip secured by a spring c-clip. were deemed statistically significant.
Imaging of treatment-induced changes in
Immunohistochemistry
Tumors at the experimental endpoint were excised, fixed in PFA and wax-embedded. 5μM sections were stained with RUNX2 (27-K, 1:50), ki-67 (SP6, 1:100) and IgG antibodies (all Santa Cruz Biotechnology) using Superpicture 3 rd Gen IHC kit (Life Technologies). Five fields per sections were viewed, scored and averaged. Immunohistochemistry staining was scored using a two approach method for extent and intensity (31) . Extent of staining was defined as the percentage of cells with nuclear immunoreactivity and was scored 0-5: negative (0); ≤10% (1); 11%-25% (2); 26%-50% (3); 51%-75% (4) and ≥76% (5). Intensity of staining was scored 0-5: negative (0)-very strong (5). Scores were averaged with 3 mice per group.
Statistical analysis
Data from qPCR analyses and tumor growth delay studies were analysed using a two-tailed student's t-test. All remaining datasets were analysed using a two-way ANOVA with Bonferroni post-test analysis. All statistical analysis was carried out using the Prism 5.0 software (GraphPad). Differences between points were deemed statistically significant with a p<0.05 (95% confidence interval).
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RESULTS
Novel uHAP OCT1002 is reduced to active form OCT1001 in hypoxic conditions
OCT1002 is electrically neutral in aqueous solution but in hypoxic tumor cells it can be reduced to the DNA-affinic cytotoxin OCT1001 ( Figure 1A ). Imaging 4 hours after OCT1002 administration on Day 7
showed extensive distribution of drug far-red fluorescence (19) in the tumor, particularly in the more hypoxic centre ( Figure 1B ). When the tumors were imaged 7 days later the bound drug is still clearly visible, particularly away from blood vessels, confirming the longevity of OCT1001 in hypoxic cells. No autofluorescence was seen in untreated tumor fragments ( Figure 1B ).
Activated OCT1002 targets hypoxic cells in vitro
Treatment of 3 prostate cancer cell-lines (LNCaP-luc, 22Rv1, PC3) at a range of OCT1002 concentrations (10 -12 to 10 -3 M) revealed no significant toxicity at concentrations of <1μM ( Figure 1C ).
When LNCaP-luc cells were grown in hypoxic conditions (0.1%) for 48 hours, there was an expected decrease in cell viability ( Figure 1D ) compared to cells grown in normoxic conditions (20%). However, treatment of these hypoxic cells with 1μM OCT1002 resulted in a further significant decrease in the viability of the cells ( Figure 1D , grey bars). In contrast, OCT1002 treatment of cells grown in normoxic conditions had no effect ( Figure 1D , white bars), indicating that the drug only targets cells in hypoxic conditions. Similar results were obtained for both 22Rv1 and PC3 cells (Supplementary Figure S2) .
We also utilised a 3D spheroid model of prostate cancer growth to illustrate the effect of OCT1002 on hypoxic LNCaP-luc cells. The increasing presence of hypoxia in growing spheroids was confirmed by the increasing levels of the hypoxic markers IGF1 and miR-210 ( Figure 2A ) and HIF1α protein ( Figure   2B ). Again, the prevalence and localisation of hypoxia-activated OCT1001 in the spheroids could be detected in the far-red spectral window ( Figure 2B , images). The developing hypoxia occurs concurrently with an increase in spheroid size over a 10 day period. Addition of bicalutamide on Day 7 significantly attenuated their growth and an even greater decrease in spheroid growth and reduction in size was found when OCT1002 was added ( Figure 2C ). Upon disaggregation, the ability of both bicalutamide-and OCT1002-treated spheroids to form colonies was significantly decreased in comparison to untreated spheroids ( Figure 2D ). In spheroids treated with OCT1002 there was a significant increase in the number of apoptotic cells ( Figure 2E, Supplementary Figure S3A ). This was consistent with the concomitant decrease in Bcl-2 protein levels and increase in Bax protein levels, as well as evidence of PARP cleavage (Supplementary Figure S3B) . Taken together, we conclude that OCT1002 is indeed activated in hypoxic conditions in vitro, resulting in increased cell death.
OCT1002 in combination with bicalutamide improves tumor growth control and reduces lung metastases
The LNCaP-luc xenograft mouse model of prostate tumorigenesis was used to measure the effect of Figure S4) .
Effect of bicalutamide on vascular density is abrogated by OCT1002
As previously (26) revealed that the genes highlighted by filtering analysis are involved in promoting cell survival.
Notably, the induction of these genes at Day 21 in response to bicalutamide was ablated by addition of OCT1002 ( Figure 5B ).
Expression of RUNX2 and pro-survival genes induced by bicalutamide is blocked by OCT1002
14 Significantly, one of these was RUNX2, which regulates expression of several targets involved in prosurvival pathways and which we had previously noted as important in the hypoxic stress response (32, 33) . Immunohistochemistry revealed that addition of OCT1002 significantly reduced the expression of RUNX2 protein, as well as Ki67 staining, in LNCaP-luc tumors ( Figure 6A ).
Furthermore, when we examined the expression of RUNX2 and several of its downstream targets, in our LNCaP-luc spheroid model, we also found that OCT1002 blocked the bicalutamide-induced upregulation of these genes ( Figure 6B ).
DISCUSSION
Understanding the physiological and molecular characteristics of the tumor microenvironment before, during and after treatment is crucial in developing and improving therapies for prostate cancer (34) . In particular, the effect of hypoxia upon tumor progression is a key consideration, since it has been consistently associated with an increasingly malignant phenotype. (12) (13) (14) (15) . In our studies, we have used a mouse LNCaP-luc xenograft model of prostate cancer; this provided an ideal method for monitoring genetic and physiological changes longitudinally. It enabled us to examine how targeting hypoxic tumor cells with the novel uHAP, OCT1002, can improve the anti-tumor efficacy of bicalutamide.
As OCT1002 is a new agent, it was first necessary to confirm that the prodrug was converted to the active form (OCT1001) in hypoxic tumors. We have shown that the drug penetrated throughout tumor fragments grown in window chambers and that it remained in the reduced form for some considerable time (>7 days)( Figure 1A and 1B). Since most of the prodrug will have been eliminated after 4 hours (half-life about 45-60 mins in mice), the fluorescent signal reflects only the highly DNA-affinic reduction product OCT1001 which is bound in hypoxic cells. We then showed that OCT1002 at high concentrations (>10 -6 M) showed cytotoxicity against 3 prostate cancer cell monolayers and that OCT1002 could target hypoxic prostate cells more effectively in hypoxia (0.1%)( Figure 1C and 1D, Supplementary Figure S2) . This confirms additional studies we have carried out showing an oxygendependent enhancement of cytotoxicity in a range of other cell lines (data not shown). We also used LNCaP-luc spheroids to more closely recapitulate in vivo tumor formation, since hypoxia develops as the spheroid grows (Figure 2A-2C) . We show that this spheroid hypoxia reduces OCT1002 and results in significant cell death, evidenced by reduced spheroid size and increased apoptotic markers.
Furthermore, spheroids had significantly reduced ability to form colonies after treatment with OCT1002 as compared to controls ( Figure 2D ). This suggests that specifically killing hypoxic cells reduces viable clonogens, which may be crucial for reducing cells with metastatic potential in vivo.
Flow cytometry suggests that OCT1002 promotes apoptosis, whereas bicalutamide induces more necrosis, presumably due to the differing modes of action of these drugs ( Figure 2E ). However, the combination of these agents needed to be explored in vivo to better assess how they would impact upon tumor growth in a more complex microenvironment. It is also notable that OCT1002 prevents the revascularisation observed during bicalutamide treatment in LNCaP-luc xenograft tumors, suggesting that the cells responsible for driving the vascular recovery are also inhibited or killed by OCT1002 (Figure 4, Supplementary Figure S5 ). This data is particularly pertinent since several chemotherapeutic drugs have also been shown to cause tumor shrinkage and vascular collapse, with a corresponding reduction in oxygen levels, even when if this is not directly linked to the mechanism of action of the drugs (35) (36) (37) . This hypoxic stress could provide an environment which selects for cells with increased metastatic potential that survive to repopulate the tumor, implying that a combination of therapies are required to prevent progression to a more malignant tumor. This was also the conclusion of another recent study which suggested that combination of ADT with inhibitors that block hypoxia-induced chemokine production may prevent emergence of CPRC in a mouse metastatic prostate (TRAMP) model (38) . In humans, this concept may explain recent results from a large clinical trial that showed using docetaxel in addition to ADT improved relapse-free survival in patients with high-risk localised prostate cancer (39) . Docetaxel would have added cytotoxic effect to the growth-slowing effect of bicalutamide, increasing the total cell kill and therefore prolonging the time to relapse. Similarly, this may also explain why widespread clinical testing of drugs which directly target tumor angiogenesis have not provided the panacea that was expected, perhaps because they drive hypoxic selection of more malignant cells, which survive to resist further treatment (40) . Indeed, the LNCaP xenograft model presented here would be ideal for studying effects of other commonly used prostate cancer drugs, such as enzalutamide and abiraterone, to investigate this phenomenon further and to help inform clinical practice.
We were also interested to see how OCT1002 would impact upon gene expression patterns that we have previously investigated in profiling the response to bicalutamide treatment alone (11) . We screened a set of 70 genes at each time-point in the treatment groups and filtered the data to identify genes which were consistently and significantly altered ( Figure 5A ). We focused on results from Day 21, since we expected the hypoxic stress at this time to be reflected in the gene signatures within the tumors. We noted that bicalutamide treatment induced an up-regulation in a large number of genes at Day 21 in response to the severe hypoxia. However, this was largely absent at this time-point when OCT1002 was combined with bicalutamide. Further examination of the genes affected at Day 21 ( Figure 5B), showed that they reflected genes involved in promoting cell survival through various mechanisms such as angiogenesis, transcription, adhesion, invasion, apoptosis and cell cycle maintenance. Notably, the induction of almost all these genes at Day 21 in response to bicalutamide was ablated by addition of OCT1002 ( Figure 5B ). These results support our proposal above that some cells can survive the bicalutamide-induced hypoxia and that this is linked to up-regulation of an array of pro-survival genes, which help re-establish the tumor vasculature. Ultimately, this could result in the hypoxia-driven selection of cells which exhibit a more aggressive, malignant phenotype.
Worryingly, this suggests that bicalutamide use in patients may in fact increase prostate cancer tumor hypoxia soon after treatment, thereby selecting for cells which have increased metastatic potential.
Our data corroborates previous studies of prostate cancer cells which have shown that hypoxia can indeed select for cells with a more malignant genotype/phenotype (13, 41, 42) , with several reports detailing the up-regulation of various genes in response to hypoxic insult, including those associated with a pro-angiogenic phenotype (43) , stem cell maintenance (44) , genetic instability (8), protection from apoptosis (45) and malignant progression (15) . With this in mind, it is significant that the upregulation of pro-survival genes is not observed at Day 21 when the OCT1002 is combined with bicalutamide. This indicates that the cells which survive the hypoxic insult, and subsequently alter gene expression, are targeted and killed, which is evidenced in increased tumor growth control.
We have previously highlighted the link between hypoxic stress and RUNX2 (32, 33) , so we were interested to see that induction of RUNX2 expression by bicalutamide treatment was effectively blocked by OCT1002 exposure. This is significant because RUNX2 expression is up-regulated in prostate (46) , breast (47, 48) and colon cancer (49) and is thought to contribute to a more aggressive, metastatic phenotype by altering expression of many genes involved in migration, invasion, metastasis, apoptosis and angiogenesis (32, 46, 49) . Similarly, in this study, the induction of RUNX2 correlated with induction of several of its downstream targets ( Figure 6A ). However, when OCT1002 was added to a bicalutamide treatment, the induction of RUNX2 and the associated targets was not observed, even though a significant hypoxic stress still existed in these tumors given that the vasculature had not been restored. Confirmation of this effect was found when we examined RUNX2 expression and other genes in our spheroid model ( Figure 6B ). This corroborates our previous work which proposes RUNX2 is a key regulator in helping cells survive the hypoxic stress. Our study suggests that the addition of OCT1002 targets those cells, thereby preventing RUNX2 up-regulation and subsequently the development of more aggressive tumor cells. Our proposed model is shown in Figure 6C , wherein the hypoxic-resistant cells within the heterogenous tumor cell population survive to repopulate the tumor, leading to relapse and CPRC development. However, addition of OCT1002 targets these cells, preventing regrowth of the microvasculature in particular and thereby exerting 19 greater tumor growth control. Future work will further characterise the exact role of RUNX2 and other key molecular changes during this process.
Conclusions
In conclusion, this study shows that the novel uHAP OCT1002 effectively targets hypoxic prostate cancer cells and improves the ability of bicalutamide to control growth of human prostate tumours in mice We propose that the enhanced efficacy is due to selective killing of cells that would otherwise survive the severe hypoxic conditions induced by vascular collapse soon after initiation of bicalutamide treatment. Since the genes up-regulated during bicalutamide treatment are predominantly pro-survival, we hypothesise that these cells survive to establish a tumor with a more malignant phenotype; this may help explain why patients treated solely with ADT exhibit a relatively early relapse. However, our data suggests that inclusion of OCT1002 at the early stage of the ADT regimen to eliminate hypoxic cells could provide a method for eradication of the more malignant hypoxic cell population. Our data provides increased understanding of the physiological and molecular changes in the prostate cancer microenvironment that occur during treatment and we suggest that more awareness of these changes should be taken into account when deciding on ADT schedules for prostate cancer patients. *p<0.05, **p<0.01, ***p<0.001, ns; not significant) (C) Proposed hypothesis for beneficial effect of
